Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Abstract

Purpose: Tislelizumab is an anti–programmed cell death protein PFS and overall survival rates were 40.8% and 84.8%, respectively. 1 (anti–PD-1) monoclonal antibody specifically designed to min-Treatment-related adverse events (TRAEs) of any grade occurred in imize binding to Fcg receptors (FcgR). 97.1% of patients; the grade ≥3 TRAE rate was low (31.4%), and only Patients and Methods: Here, we present the extended 3-year 8.6% of patients experienced adverse events leading to treatment follow-up of a phase II study of tislelizumab in 70 patients with discontinuation. Correlative biomarker analysis showed that FcgRI-relapsed/refractory classical Hodgkin lymphoma (cHL) who failed expressing macrophages had no observed impact on either the CR or were ineligible for autologous stem cell transplantation. rate or PFS achieved with tislelizumab, which may be potentially Results: With a median follow-up of 33.8 months, the overall related to its engineered Fc region. response rate by the independent review committee was 87.1%, and Conclusions: With extended follow-up, tislelizumab yielded the complete response (CR) rate was 67.1%. Responses were durable long-term benefits and demonstrated a favorable safety profile for as shown by a median duration of response of 31.3 months, and patients with relapsed/refractory cHL. This trial was registered at median progression-free survival (PFS) of 31.5 months.